278 related articles for article (PubMed ID: 37805494)
21. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
Longo M; Caruso P; Scappaticcio L; Maiorino MI; Bellastella G; Capuano A; Esposito K; Giugliano D
Diabetes Obes Metab; 2024 Apr; 26(4):1492-1501. PubMed ID: 38234208
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
23. Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhang A; Luo X; Meng H; Kang J; Qin G; Chen Y; Zhang X
Front Endocrinol (Lausanne); 2020; 11():604250. PubMed ID: 33519713
[TBL] [Abstract][Full Text] [Related]
24. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
25. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
26. Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Lugner M; Sattar N; Miftaraj M; Ekelund J; Franzén S; Svensson AM; Eliasson B
Cardiovasc Diabetol; 2021 Mar; 20(1):67. PubMed ID: 33752680
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
28. Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study.
Sung HL; Hung CY; Tung YC; Lin CC; Tsai TH; Huang KH
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3784. PubMed ID: 38402457
[TBL] [Abstract][Full Text] [Related]
29. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
Cavender MA; Norhammar A; Birkeland KI; Jørgensen ME; Wilding JP; Khunti K; Fu AZ; Bodegård J; Blak BT; Wittbrodt E; Thuresson M; Fenici P; Hammar N; Kosiborod M;
J Am Coll Cardiol; 2018 Jun; 71(22):2497-2506. PubMed ID: 29852973
[TBL] [Abstract][Full Text] [Related]
30. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
Nassif ME; Kosiborod M
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
[TBL] [Abstract][Full Text] [Related]
31. Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction.
Trombara F; Cosentino N; Bonomi A; Ludergnani M; Poggio P; Gionti L; Baviera M; Colacioppo P; Roncaglioni MC; Leoni O; Bortolan F; Agostoni P; Genovese S; Marenzi G
Cardiovasc Diabetol; 2023 Feb; 22(1):26. PubMed ID: 36747186
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the Safety of Sodium-Glucose Cotransporter-2 Inhibitors in a Nationwide Veterans Health Administration Observational Cohort Study.
Patil T; Cook M; Hobson J; Kaur A; Lee A
Am J Cardiol; 2023 Aug; 201():281-293. PubMed ID: 37393731
[TBL] [Abstract][Full Text] [Related]
33. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease.
Pan HC; Chen JY; Chen HY; Yeh FY; Huang TT; Sun CY; Wang SI; Wei JC; Wu VC
JAMA Netw Open; 2024 Jan; 7(1):e2350050. PubMed ID: 38170522
[TBL] [Abstract][Full Text] [Related]
34. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
Zhou B; Shi Y; Fu R; Ni H; Gu L; Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
Front Endocrinol (Lausanne); 2022; 13():907340. PubMed ID: 35692406
[TBL] [Abstract][Full Text] [Related]
35. Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis.
Liu T; Fan Z; Xiao B; He C; Wang S
Cardiovasc Diabetol; 2024 Mar; 23(1):106. PubMed ID: 38528542
[TBL] [Abstract][Full Text] [Related]
36. Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis.
Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Raparelli V; Pilote L
Int J Cardiol; 2020 Jul; 310():147-154. PubMed ID: 32303419
[TBL] [Abstract][Full Text] [Related]
37. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study.
Kosiborod M; Birkeland KI; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Jørgensen ME; Wittbrodt ET; Thuresson M; Bodegård J; Hammar N; Fenici P;
Diabetes Obes Metab; 2018 Aug; 20(8):1983-1987. PubMed ID: 29569378
[TBL] [Abstract][Full Text] [Related]
38. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.
Shi N; Shi Y; Xu J; Si Y; Yang T; Zhang M; Ng DM; Li X; Xie F
Front Public Health; 2021; 9():668368. PubMed ID: 34164370
[No Abstract] [Full Text] [Related]
39. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia.
Real J; Vlacho B; Ortega E; Vallés JA; Mata-Cases M; Castelblanco E; Wittbrodt ET; Fenici P; Kosiborod M; Mauricio D; Franch-Nadal J
Cardiovasc Diabetol; 2021 Jul; 20(1):139. PubMed ID: 34243779
[TBL] [Abstract][Full Text] [Related]
40. Comparative safety of different recommended doses of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials.
Chen L; Xue Q; Yan C; Tang B; Wang L; Zhang B; Zhao Q
Front Endocrinol (Lausanne); 2023; 14():1256548. PubMed ID: 38027214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]